Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)

Posted by Francis Steltz on Jul 31st, 2026

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 23,688 call options on the company. This is an increase of approximately 136% compared to the typical volume of 10,058 call options.

Teva Pharmaceutical Industries Stock Up 2.1%

Shares of NYSE:TEVA opened at $35.45 on Friday. The company has a market cap of $40.76 billion, a price-to-earnings ratio of 59.09, a PEG ratio of 3.67 and a beta of 0.86. Teva Pharmaceutical Industries has a 12 month low of $14.99 and a 12 month high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a 50-day moving average price of $33.22 and a 200 day moving average price of $32.72.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.59% and a net margin of 4.08%. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Richard Daniell sold 30,000 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the sale, the executive vice president owned 55,755 shares in the company, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. This trade represents a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 300,493 shares of company stock valued at $10,537,510 over the last 90 days. Company insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TEVA. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $25,000. Cornerstone Planning Group LLC grew its holdings in Teva Pharmaceutical Industries by 547.1% during the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares during the last quarter. Allworth Financial LP raised its position in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares during the period. EverSource Wealth Advisors LLC raised its position in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after purchasing an additional 345 shares during the period. Finally, Global Retirement Partners LLC lifted its stake in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TEVA shares. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Truist Financial upped their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Friday, July 17th. Finally, Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Get Our Latest Stock Report on TEVA

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Teva reported second-quarter revenue of approximately $4.14 billion, ahead of consensus estimates of $4.02 billion. Innovative medicines grew 43% year over year in local-currency terms, helping offset weaker generics sales. Teva Delivers Strong Q2 Results and Raises Outlook
Positive Sentiment: Management raised its 2026 revenue outlook to $16.5 billion-$16.9 billion and increased projections for its three key innovative brands, signaling confidence in the company’s branded-drug growth strategy. Teva Outlines Higher 2026 Revenue Outlook
Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million, supporting optimism about its long-acting injectable portfolio. UZEDY Record Q2 Net Sales
Positive Sentiment: Piper Sandler reportedly forecast substantial potential appreciation for TEVA, adding to bullish sentiment following the results. Piper Sandler Forecasts Strong Price Appreciation
Neutral Sentiment: Options activity was unusually elevated: traders bought about 23,688 calls on Wednesday, followed by roughly 27,659 puts on Thursday. The activity indicates heightened speculation but does not establish a clear directional signal. Unusually Large Options Trading
Negative Sentiment: Second-quarter EPS of $0.02 missed the $0.08 consensus estimate, while acquisition-related costs and impairment charges contributed to a reported net loss of $576 million. Full-year EPS guidance of $1.91-$2.11 also remains below the $2.17 consensus estimate. Teva Q2 Earnings Lag Estimates

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.